
Elanco Animal Health (ELAN) Stock
Global animal health company selling pet and livestock medicines. Here's the price, business snapshot, and what's worth knowing about Elanco Animal Health in August 2026.
Elanco Animal Health Inc (ELAN) is a global animal health company that develops and sells pharmaceuticals, vaccines and parasiticides for companion animals and livestock. Investors should know its business is split between higher-margin companion-animal products (pets) and larger-volume livestock offerings, giving exposure to both consumer-driven and agricultural demand cycles. Growth has been shaped by product launches and acquisitions, while margins and cash flow can be influenced by integration costs, commodity-linked livestock markets and regulatory approvals. Key risks include competition, pricing pressure, and the need for ongoing R&D investment. The company’s operations are global, so currency and regional regulatory environments matter. This summary is for general educational purposes only and is not personal financial advice; values can rise and fall and investors should consider their risk tolerance and seek independent advice where needed.
About This Stock
ELANCO ANIMAL HEALTH INC
ELAN
Current Price
$24.39
Potential 12 Month Profit
-32.34%
Sector
Healthcare
Industry
Pharmaceuticals
Ticker
ELAN
Market Cap
$12.24B
Potential 12 Month Profit
-32.34%
Sector
Healthcare
Industry
Pharmaceuticals
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Elanco's stock, which has a target price slightly below its current price.
Financial Health
Elanco is generating solid revenue and cash flow, indicating strong operational performance and stability.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Companion-Animal Momentum
Companion products often command higher margins and steady demand as pet ownership rises, though results can vary and competition is strong.
Global Livestock Exposure
A large livestock portfolio gives exposure to agricultural cycles and emerging-market protein demand, but commodity swings and regulatory factors add volatility.
Pipeline and M&A
R&D and strategic acquisitions can boost future revenues, yet integration costs and approval risks mean outcomes are uncertain.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.